Eikon Therapeutics, Inc.
EIKNCIK 0001861123 · Every Form 4 filed by insiders at this issuer. See financials →
Annual report (10-K)
Latest 10-K filed Mar 30, 2026. Sentiment + YoY language diff vs prior year. Read sections →
Signal:No prior 10-KFull-doc fallback
Full filing:tone -0.0146
Sentiment via Loughran-McDonald lexicon · YoY diff via Jaccard similarity + paragraph set difference.
Recent 8-K announcements
Per-item disclosure feed. Item 2.02 is the earnings release.
Top insiders
Most active reporters at Eikon Therapeutics, Inc.
| Name | Roles | Filings |
|---|---|---|
| Frazier Kenneth C | Director | 2 |
| Perlmutter Roger M | OfficerDirector | 2 |
| Wolfe Josh | Director10% Owner | 2 |
| Baynes Roy D. | Officer | 1 |
| Bowie Alfred Lloyd Jr. | Officer | 1 |
Showing 1-5 of 29
Page 1 of 6Next
Top performers
Insiders ranked by realized 90-day signed return on their open-market trades at Eikon Therapeutics, Inc.. Minimum 3 scored trades. Returns are signed - a sale followed by a rally counts against the insider.
| # | Insider | Trades | Win rate | Avg | Median | Best | Worst |
|---|---|---|---|---|---|---|---|
| 1 | Column Group IV Gp, LP | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 2 | Column Group IV, LP | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 3 | Column Group IV-A, LP | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 4 | Column Group Opportunity III Gp, LP | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 5 | Column Group Opportunity III, LP | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 6 | Kutzkey Tim | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 7 | Svennilson Peter | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 8 | Tcg Opportunity III Gp, LLC | 3 | 0% | -36.8% | -36.8% | -36.8% | -36.8% |
| 9 | Wolfe Josh | 4 | 0% | -33.5% | -33.5% | -33.5% | -33.5% |
All filings
13 Form 4 / 4-A filings, newest first
| Filed | Top transaction | Shares | Price | Value | ||
|---|---|---|---|---|---|---|